A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study

Status Completed

Clinical Trial Summary

Twenty-Eight (28) subjects (12 for cohort 1 and 16 for cohort 2 ) will be included in the study. Subjects in each cohort will be injected with a different dose of RZL-012. The total of 28 subjects will be enrolled in 2 clinical sites.

Clinical Trial Description

This is a single blinded, randomized, placebo-controlled, 2-cohort clinical study in healthy volunteers. Cohort 1 will be comprised of 8 active (RZL-012) and 4 placebo subjects. Cohort 2 will be comprised of 16 subjects wuth at least 4 placebo subjects. All subjects will receive a single dose of RZL-012 or vehicle into the submental area, after which they will be monitored for safety and efficacy during 84 days of follow-up. Subjects will be blinded to study treatment while physicians will not be blinded. The study will be composed of 2 treatment cohorts, 12 in cohort 1 and 16 in cohort 2. The study will be conducted in 2 clinical sites. Per each study cohort, subjects will be randomized to receive active or placebo treatment according to a randomization program that will be prepared prior to study initiation. Each clinical site will have at least one active and one placebo treatment subject per each study cohorts. In case of slow enrollment in one of the sites, other sites may complete the enrollment of subjects in each cohort. Cohort 1 (N=12) - Each subject will be dosed with up to 120 mg RZL-012 (depending on submental fat area) or vehicle. Cohort 2 (N=16) - Each subject will be dosed with up to 240 mg RZL-012 (depending on submental fat area) or vehicle. Treatment of cohort 2 will start following cohort 1 day 28 data. An independent Data Safety Monitoring Board (DSMB) will review safety and tolerability data for cohort 1 subjects, 28 days after injection, and decide whether it is safe to increase the dose for the next study cohort. The decision to proceed to the cohort 2 will be made within 30 days (28 days + 2 days) after injection of the last dosed subject in cohort 1. The DSMB will be comprised of two independent MDs with expertise in the aesthetic area and in conduction of clinical trials. In case of serious safety concerns (e.g. prolonged severe swelling or severe pain following injection) among cohort 1 subjects receiving the 120mg dose, sponsor and DSMB may decide to reduce or stay with the 120mg/subject dose level for cohort 2 subjects. ;

Study Design

Related Conditions & MeSH terms

Submental Fat

Clinical Trial Details

NCT number	NCT04086823
Study type	Interventional
Source	Raziel Therapeutics Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	February 25, 2020
Completion date	September 16, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05476679` - Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events	Phase 1/Phase 2
Completed	`NCT04144049` - A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat	Phase 2
Active, not recruiting	`NCT05154955` - A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat	Phase 2
Completed	`NCT04258761` - A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")	Phase 2
Completed	`NCT05763160` - An Open-label Study That Will Test a Second Treatment Session of RZL-012.	Phase 2
Completed	`NCT03946592` - Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat	Phase 3
Completed	`NCT04867434` - Efficacy and Safety of RZL-012 on Submental Fat Reduction	Phase 2
Completed	`NCT05466448` - An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.	Phase 1/Phase 2
Completed	`NCT02159729` - Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101	Phase 2
Completed	`NCT05195112` - Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat	Phase 3
Completed	`NCT03005717` - Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat	Phase 2
Completed	`NCT02163902` - Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101	Phase 3
Completed	`NCT05476094` - Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms